

ASX Release

EMVision Medical Devices Ltd
ACN 620 388 230
Suite 4.01, 65 Epping Rd
Sydney NSW 2113
02 8667 5337
contact@envision.com.au

OVERSUBSCRIBED SHARE PURCHASE PLAN RAISES \$2.0 MILLION

EMVision Medical Devices Limited (ASX:EMV) (“EMVision” or the “Company”) is pleased to advise that the Share Purchase Plan (SPP), announced on 17 September 2025 has successfully completed, raising approximately \$2.0m, with a total of 1,030,928 million new fully paid ordinary shares and 773,196 attaching options to be issued. The new securities will be issued on establishment of the new ASX listed option code which is expected imminently.

Together with the recently announced \$12.0m Placement, EMVision has raised a total of \$14.0m, which puts the Company in a strong financial position to advance through major milestones, including pivotal trial readout, supporting FDA submission, and initial commercialisation activities for the emu™ device, as well as advancing the First Responder program through clinical trials, production readiness and regulatory preparation.

The SPP was heavily oversubscribed. As a result of this strong demand, and in accordance with the SPP Terms (which was targeting \$1.0m with the ability to accept oversubscriptions of a further \$1.0m), applications were required to be scaled back in accordance with the SPP Offer Document.

The methodology involved applying an equal scale back to applications, with a c10% preference given to shareholders that had supported the SPP earlier in the offer period. A small number of applicants with very small shareholdings that had applied for amounts materially above their shareholding value were scaled back to a minimum allocation to ensure a more equitable allocation was given to a broader group of shareholders.

We thank all shareholders for their support.

Authorised for release by the Managing Director and Company Secretary of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys	Scott Kirkland
Investors & Media	CEO and Managing Director
+61 400 400 380	+61 2 8667 5337
andrew.keys@keysthomas.com	skirkland@envision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neurodiagnostic devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane www.envisionmedical.com

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.